Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone. My name is Kahayalani, and I will be your conference operator today. At this time, I would like to welcome you to the Chimera Therapeutics fourth quarter 2025 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, and if you've joined via the webinar, please use the raise hand icon, which can be found at the bottom of your webinar application. If you've joined by phone, please dial star 9 on your keypad to raise your hand. At this time, I'd like to turn the call over to Justine Konigsberg, Vice President, Investor Relations. Good morning and welcome to Chimera Therapeutics quarterly update conference call. Joining me today are Noah Meinolfi, our founder, president, chief executive officer, Jared Golub, our chief medical officer, and Bruce Jacobs, our chief financial officer. Following our prepared remarks, we will open the call for questions from our publishing analysts. Please use the raise hand icon to indicate that you'd like to ask a question, and we ask that you limit your question to one and a brief follow-up so we can accommodate everyone. Before we begin, I would like to remind you that today's discussion will include forward-looking statements subject to risks and uncertainties described in our most recent Form 10-K filed with the SEC. Please note that any forward-looking statements speak only as of today's date. And with that, I will now turn the call over to Nello. Thank you, Justine, and thank you, everybody, for joining us this morning. As this is our year-end 2025 call, I wanted to spend a few minutes recapping what was an incredible year for Chimera. Those of you that know us well app...